Trial Profile
Dose Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Randomized, Controlled, Observer Blind Phase II Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs VLA 84 (Primary)
- Indications Clostridium difficile infections
- Focus Pharmacodynamics
- Sponsors Valneva
- 25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
- 25 Jul 2016 Final study results until day 210, published in a Valneva media release.
- 11 May 2016 Topline results will be presented at the American Society for Microbiology symposium (ASM Microbe 2016), according to a Valneva media release.